For additional information regarding such risks, the company urges you to review its 10-Q and 10-K SEC filings. I would now like to turn the conference over to Dr. Mitchell Steiner, Veru Inc.’s ...
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight ...
Thank you for joining our second quarter fiscal year 2020 and earnings call. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of ...
Q2 fiscal 2026 Management View "Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases," said ...
Yi Chen: Got it. My next question is, do you expect the FC2 sales to return to the levels seen in the fiscal first and second quarter of 2022? And if so, how soon do you expect to return to that level ...
Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients diagnosed ...
Veru, Inc. (NASDAQ:VERU) disclosed:On March 14, 2023, at the Oppenheimer 33rd Annual Healthcare Conference, Dr. Mitchell Steiner, M.D., Chairman, President and Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results